

**CD207<sup>+</sup> CD103<sup>+</sup> dermal dendritic cells cross-present keratinocyte-derived antigens irrespective of the presence of Langerhans cells**

Sandrine Henri, Lionel Franz Poulin, Samira Tamoutounour, Laurence Ardouin, Martin Guillems, Béatrice de Bovis, Elisabeth Devillard, Christophe Viret, Hiroaki Azukizawa, Adrien Kissenpfennig, and Bernard Malissen

Vol. 207, No. 1, January 18, 2010. Pages 189–206.

The authors regret that data was presented incorrectly in Table I of their article. The errors have been corrected in the html and pdf versions of the article. The corrected table is presented below:

**Table I.** Phenotype and frequency of the five skin DC subsets prior to and following their migration to CLNs

Skin subset	Phenotypes	Frequency
		%
<b>Epidermis</b>		
Epidermal LCs	CD207 <sup>+</sup> , CD11b <sup>int</sup> , CD103 <sup>−</sup> , EpCAM <sup>++</sup> , CD24 <sup>+</sup> , Sirpα <sup>+</sup>	100 ± 1
<b>Dermis</b>		
LCs in transit	CD207 <sup>+</sup> , CD11b <sup>int</sup> , CD103 <sup>−</sup> , EpCAM <sup>++</sup> , CD24 <sup>+</sup> , Sirpα <sup>+</sup>	6.4 ± 1
CD207 <sup>+</sup> CD103 <sup>−</sup> DDCs	CD207 <sup>+</sup> , CD11b <sup>low</sup> , CD103 <sup>−</sup> , EpCAM <sup>−/low</sup> , CD24 <sup>+</sup> , Sirpα <sup>−</sup>	2.8 ± 0.5
CD207 <sup>+</sup> CD103 <sup>+</sup> DDCs	CD207 <sup>+</sup> , CD11b <sup>low</sup> , CD103 <sup>+</sup> , EpCAM <sup>−/low</sup> , CD24 <sup>+</sup> , Sirpα <sup>−</sup>	2.6 ± 0.6
CD207 <sup>−</sup> CD11b <sup>−</sup> DDCs	CD207 <sup>−</sup> , CD11b <sup>−/low</sup> , CD103 <sup>−</sup> , EpCAM <sup>−</sup> , CD24 <sup>−</sup> , Sirpα <sup>low</sup>	16.3 ± 1.3
CD207 <sup>−</sup> CD11b <sup>+</sup> DDCs	CD207 <sup>−</sup> , CD11b <sup>high</sup> , CD103 <sup>−</sup> , EpCAM <sup>−</sup> , CD24 <sup>−</sup> , Sirpα <sup>+</sup>	65.8 ± 5
<b>CLNs</b>		
mLCs	CD207 <sup>+</sup> , CD11b <sup>−/low</sup> ↓, CD103 <sup>−</sup> , EpCAM <sup>+</sup> , CD24 <sup>+</sup> , Sirpα <sup>+</sup>	9.5 ± 2.9
CD207 <sup>+</sup> CD103 <sup>−</sup> mDDCs	CD207 <sup>+</sup> , CD11b <sup>−/low</sup> , CD103 <sup>−</sup> , EpCAM <sup>+</sup> ↑, CD24 <sup>+</sup> , Sirpα <sup>+</sup> ↑	7.0 ± 4.2
CD207 <sup>+</sup> CD103 <sup>+</sup> mDDCs	CD207 <sup>+</sup> , CD11b <sup>−/low</sup> , CD103 <sup>+</sup> , EpCAM <sup>+</sup> ↑, CD24 <sup>+</sup> , Sirpα <sup>low</sup>	13.5 ± 4.5
CD207 <sup>−</sup> CD11b <sup>−</sup> mDDCs	CD207 <sup>−</sup> , CD11b <sup>−</sup> , CD103 <sup>bim</sup> ↑, EpCAM <sup>bim</sup> ↑, CD24 <sup>bim</sup> ↑, Sirpα <sup>+</sup> ↑	20.8 ± 2.5
CD207 <sup>−</sup> CD11b <sup>+</sup> mDDCs	CD207 <sup>−</sup> , CD11b <sup>+</sup> , CD103 <sup>bim</sup> ↑, EpCAM <sup>int</sup> ↑, CD24 <sup>int</sup> ↑, Sirpα <sup>+</sup>	35.2 ± 2.6

The percentage ± SEM of each subset among MHCII<sup>+</sup> (epidermis and dermis) or MHCII<sup>high</sup> CD11c<sup>inter-to-high</sup> (CLN) cells were calculated from at least six independent experiments. Upward and downward pointing arrows indicate markers that were up-regulated or down-regulated, respectively, upon migration to CLNs. Bim, bimodal.